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Segregated calcium stores are important for stretch-induced calcium
signaling in smooth muscle cells: implication in pulmonary hypertension
Guillaume Gilbert, Thomas Ducret, Jean-Pierre Savinea, Roger Marthan,
Jean-François Quignard
Université de Bordeaux, Centre de Recherche Cardio-Thoracique,
INSERM U1045, Bordeaux, France
Pulmonary arterial smooth muscle cells (PASMC) are submitted to stretch
forces exerted by the blood pressure. They can transduce a mechanical stim-
ulus of stretch into a biological response of contraction, a mechanism called
myogenic tone which involves Ca2+ influx through stretch-activated channels
(SAC). We investigate how the subcellular organization of Ca2+ stores in
PASMC (sarcoplasmic reticulum (SR), lysosomes and mitochondria) is impor-
tant for the Ca2+ response to stretch during PH.
Studies were performed in freshly isolated PASMC from control rats and
rats with a pulmonary hypertension induced by an injection of monocrotaline
(MCT). Inward currents from SAC were recorded after a negative pressure
applied by a patch-clamp pipette. Cytosolic Ca2+ was also measured with the
fluo4 probe and mitochondrial Ca2+ with the rhod2 probe after an osmotic
shock. A pharmacological approach coupled with different coimmuno-
labelings of ryanodine receptors (RyR) and SERCA2 pumps was used to
investigate which RyR subtype is involved in Ca2+ response to stretch.
PASMC exhibit segregated Ca2+ stores: a subplasmalemnal SR store with
RyR1 and SERCA2b, associated to mitochondria and a perinuclear SR store
with RyR3 and SERCA2a. We showed that a stretch of PASMC induces an
inward Ca2+ influx through SAC that is amplified by a Ca2+ release by RyR1,
which is buffered by mitochondria. In MCT rats, the subcellular organization of
RyR subtypes is modified: RyR3 and SERCA2a are not only expressed in a
perinuclear area but also in a subplasmalemnal level. This is correlated with a
different organization of mitochondria. In MCT rats, this new organisation leads
to a greater amplification by all RyR subtypes and to a higher Ca2+ increase
induced by stretch. Furthermore, the Ca2+ response to stretch is enhanced by a
mechanism independent on extracellular Ca2+, involving caveolae.
The spatial organization of Ca2+ stores in PASMC is important for cell sig-
naling and plays a causal role in PH.
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Aims: Because mineralocorticoid receptor (MR) antagonists have shown effi-
cacy in slowing down the progression of heart failure after myocardial infarction
(MI), there is interest to elucidate the cell-specific involvement of MR. Indeed, the
role of MR in vascular smooth muscle cells (VSMC) in heart failure, especially its
impact on coronary circulation, has never been investigated.
Methods and Results: Two months after MI, mice lacking the MR specifi-
cally in VSMC (MI-MRSMKO) and mice treated with the MR antagonist finere-
none (MI-fine) had better coronary function than control (MI-CTL), as assessed
by acetylcholine-induced relaxation of isolated arteries (relaxation %: MI-CTL:
36±5, MI-MRSMKO: 54±3, MI-fine: 76±4; P<0.05). Furthermore, MRI showed
that the coronary reserve was increased (ml/mg/min: MI-CTL: 1.1±0.5, MI-
MRSMKO: 4.6±1.6, P<0.05; MI-fine: 3.6±0.7, P<0.01). Incubation with the
NAPDH-oxidase inhibitor apocynin of coronary arteries improved acetylcholine-
induced relaxation in MI-CTL to a higher extent than in MI-MRSMKO and MI-
fine mice, suggesting that MR antagonism reduces oxidative stress-mediated
endothelial dysfunction. Indeed, incubation of coronary arteries from non-infarcted
animals with 10-9M angiotensin II induced oxidative stress and impaired acetyl-
choline-induced relaxation in CTL mice, but not in MRSMKO or in 4 weeks
finerenone-treated mice. These improvements in coronary function were accompa-
nied in MI-MRSMKO mice by reduced LV fibrosis and improved LV function.
Conclusion: After MI, VSMC-specific MR invalidation benefits LV dys-
function, likely through improvement of coronary reserve and of coronary
endothelial function, demonstrating for the first time the deleterious role of
smooth muscle MR activation in heart failure. Furthermore, systemic MR
blockade by finerenone confers additional functional improvements.
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Contribution of large conductance Ca(2+)-activated K(+) channels to
vasorelaxation induced by cAMP-phosphodiesterases inhibitors is
blunted in coronary arteries from rats with heart failure
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3’-5’-cyclic adenosine monophosphate (cAMP) is an important mediator of
vasorelaxation. In vascular smooth muscle, cellular cAMP concentrations are
mainly regulated by type 3 and 4 phosphodiesterases (PDE3 & PDE4). Large
conductance Ca(2+)-activated K(+) (BK) channels are reported to mediate
cAMP-induced relaxation. Here, we sought to clarify whether BK channels are
key players in the regulation of tone by PDE activities in rat coronary arteries
(CA), and if this contribution is altered in congestive heart failure (CHF). CA
were isolated from rats with CHF sacrificed 22 weeks after surgical stenosis of
the ascending aorta. Age-matched « sham » animals were used as controls. CA
were isolated and mounted on a myograph. Maximal contraction was obtained
using high K(+) solution. Relaxations induced by inhibitors of PDE4 (Ro-20
1724, Ro, 10μM) or the PDE3 (Cilolstamide, Cil, 1μM) were studied in CA con-
tracted with the thromboxane analogue U46619 (1-2μM) and incubated or not
with iberiotoxin (IBTX, 100nM), a selective BK channel blocker. CA isolated
from rats displaying robust signs of CHF showed a 78% reduction of maximal
contraction (P<0.001, N=5-7) and reduced relaxing response to acetylcholine
(–55%, P< 0.01), compared to CA from sham rats. Ro and Cil relaxed sham CA
to respectively 31±13% and 14±5% of U46619 tone (N=6). In the presence of
IBTX, these responses decreased to 3±1% (N=5, P<0.05) and 4±3% (N=4). In
CHF rats, Ro relaxed CA to 7±4% and Cil to 27±4% (N=4), whereas IBTX had
no effect either on responses to Ro (17±8 %, N=5) or Cil (26±6%, N=4). Simul-
taneous addition of Cil and Ro relaxed sham CA to 79±10% (N=7), an effect
reduced by IBTX (20±9%, N=6, P<0.01). Interestingly, Cil and Ro together
relaxed CHF CA to 69±9% but this was not altered by IBTX (69±14%, N=5-6).
These results show that, in rat CA, BK channels are important effectors of
relaxing responses to PDE3 and PDE4 inhibition. In CHF, specific contribution
of BK channels to these responses is lost.
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Background: We have previously shown that the AMPK specific acti-
vator, A769662, is able to block phenylephrine (PE)-induced hypertrophy
without affecting the previously identified AMPK-related key regulators of
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cardiac hypertrophy, namely protein synthesis, NFAT and MAP kinase sig-
naling. Hence, this study was undertaken to identify a novel mechanism by
which AMPK can regulate cardiac hypertrophy.
Methods: Hypertrophy was induced in neonatal rat cardiomyocytes
(NRVMs) using PE for 24h and AMPK was chronically activated with
A769662. Hypertrophy was evaluated by immunostaining and cell surface
area measurement. In vivo cardiac hypertrophy was induced by Angiotensin II
(AngII) infusion by osmotic mini-pumps and AMPK was activated by met-
formin in drinking water. Protein expression, AMPK phosphorylation and O-
GlcNAc levels were evaluated by QPCR and western blot.
Results: First, we showed that PE-dependent cardiomyocyte hypertrophy
was accompanied by an increase in O-GlcNAc levels. This hypertrophy was
prevented by A769662 and this was associated with a decrease in O-GlcNAc
levels. Then, using hexosamine biosynthesis pathway activators, i. e
PUGNAc or glucosamine, we showed that increase in O-GlcNAc levels was
able to reverse the anti-hypertrophic effect of AMPK activation in NRVMs.
Similar results were obtained in adult rat cardiomyocytes. On the other
hand, inhibition of hexosamine biosynthesis pathway by Azaserine or DON
inhibited PE-induced cardiomyocyte hypertrophy and this effect was
reversed by PUGNAc or glucosamine. In vivo experiments confirmed these
in vitro data. Indeed, metformin was able to reduce cardiac hypertrophy and
this correlated with a decrease in O-GlcNAc levels in WT mice but not in
AMPKα2 knockout mice.
Conclusion: Collectively, our results suggest that AMPK regulates cardiac
hypertrophy mainly by inhibiting O-GlcNAcylation signaling. AMPK and O-
GlcNAcylation signaling could be putative new therapeutic targets for treat-
ment of cardiac hypertrophy.
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Endothelium dependent relaxation and T-type voltage-gated calcium
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T-type voltage-gated calcium channels (T-VGCC) are involved in the
regulation of pulmonary arterial tone. Besides their roles in smooth muscle
cell contraction, we investigate if T-VGCC could control vascular relaxation
via endothelial calcium signaling regulation in mouse pulmonary arteries.
Immunofluorescence labeling indicates that endothelial cells (as well as
smooth muscle cells) express T-VGCC proteins (Cav3.1 and Cav3.2 isotypes).
We show that nitric oxide (NO)-dependent relaxation induced by acetylcho-
line is reduced in the presence of T-VGCC antagonists (mibefradil, NNC 55-
0396) and in Cav3.1 knock-out mice. Acetylcholine induces an endothelial
intracellular calcium increase which is reduced by the same types of inhibi-
tors. By contrast, endothelium dependent relaxation induced by beta 2 adren-
ergic stimulation (with procaterol), which is calcium independent, is not
inhibited by mibefradil or in Cav3.1 knock-out mice. Furthermore, in patho-
logical condition (pulmonary hypertension induced by a chronic hypoxia),
acetylcholine-mediated relaxation is reduced and even more in Cav3.1 knock-
out mice. In summary, in mice pulmonary arteries, acetylcholine and calcium-
dependent dilatation require T-VGCC. The present findings suggest that cal-
cium influx through T-VGCC mediate a dual effect in pulmonary artery: a
contraction when it occurred in smooth muscle cells and a dilatation when it
occurred in endothelial cells.
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Smooth muscle specific Rac1 deficiency induces hypertension by over
activation of RhoA/Rho-kinase signaling pathway
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The small GTPase RhoA and its target, Rho kinase, play essential role
in both blood pressure regulation and vascular smooth muscle contraction.
Increasing evidence implicates over activation of this signaling pathway as
a critical event in the pathogenesis of hypertension. Interestingly, it has
been recently described that Rac1 could antagonize RhoA-dependent func-
tions. However, the role of Rac1 in the regulation of vascular tone and
blood pressure is not fully elucidated. Here we assessed the hypothesis
that smooth muscle Rac1 participates in the control of blood pressure. To
define the role of vascular smooth muscle cells (vSMC) Rac1 in vivo in
the control of blood pressure, we generated inducible, smooth muscle
(SM)-specific Rac1 knockout mice (SM-Rac1-KO) and analyzed cardio-
vascular parameters. Following induction of Rac1 deletion, SM-Rac1-KO
mice rapidly develop high systolic blood pressure (+15±2 mmHg, n=19,
p=0.02). Treatment with the Rho kinase inhibitor fasudil decreases systolic
arterial pressure to a level similar in control and SM-Rac1-KO mice sug-
gesting that RhoA/Rho kinase signaling is involved in the rise in systolic
blood pressure induced by SM-Rac1 deletion. This is confirmed by immu-
noblot analysis in aorta that reveals an increase of activated RhoA (348±
19% of control, n=4, p<0.05) and Rho-kinase activity (390±25% of con-
trol, n=4, p<0.05) in SM-Rac1-KO compared to control mice. This over-
activation of RhoA signaling in SM-Rac1-KO mice is associated with a
75%-reduction of the inhibitory phosphorylation of RhoA on Ser188 com-
pared to control mice. At functional level, while NO production is not
modified, NO-dependent vasodilation is decreased in SM-Rac1-KO
arteries (≈  56% of control). By in vitro experiments in vSMC, we demon-
strate that the loss of Rac1 leads to a defective production of cGMP and a
down-regulation of the cGMP-dependent kinase-mediated inhibition of
RhoA/Rho kinase signaling. These results thus identified a blood pressure-
lowering effect of vSMC Rac1, that tonically antagonizes RhoA/Rho
kinase activity to modulate arterial tone and blood pressure through
cGMP/ cGMP-dependent kinase pathway.
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Estradiol (E2) regulates gene transcription through nuclear Estrogen
Receptor alpha (ERα) thanks to two Activation Functions, AF-1 and AF-
2, but can activate membrane ERα and thereby rapid « non genomic »
signals. Some tissue-specific stimulatory roles of these ERα functions
have already been described: for instance ERαAF1 and membrane ERα
activation are each necessary and sufficient to induce endometrial epithe-
lial proliferation and to accelerate endothelial healing respectively in
response to E2.
E2 can also inhibit vascular smooth muscle cell proliferation, but the
mechanisms of this action are poorly recognized. Using a mouse model of
femoral artery injury, we found that 1) E2 prevents intimal smooth muscle
hyperplasia. 2) Selective inactivation of ERα in smooth muscle cells abrogates
this protective action, whereas its endothelial and hematopoietic inactivation
did not alter this effect. 3) Estrogen dendrimer conjugate, a selective activator
of membrane ERa, fail to prevent intimal hyperplasia. 4) E2 does not inhibit
post-injury arterial smooth muscle cell proliferation in mice selectively defi-
cient in ERαAF1 (through deletion of the N-terminal A/B domain which har-
bors this function), demonstrating that ERαAF1 is necessary to mediate this
effect, 5) Finally, tamoxifen, a selective partial AF-1 activator of ERα, is suf-
ficient to prevent the hyperplasia. Altogether, we demonstrate here, for the
first time, that ERαAF1 activation is both necessary and sufficient to prevent
post-injury arterial smooth muscle cell proliferation, in striking contrast to its
stimulatory action on the endometrial epithelium. This underlines the exquisite
tissue-specific actions of ERα subfunctions as well as of selective ER modu-
lators, and shed some light on one of the most intriguing mysteries of biology
of estrogens.
